Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 30, 2026.

As of June 30, 2026, Arrowhead Pharmaceuticals, Inc. has 141.13M shares outstanding.

As of June 30, 2026, Arrowhead Pharmaceuticals, Inc. maintains a current ratio of 5.90, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 211.07, indicating elevated leverage, while an interest coverage ratio of -2.17 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Arrowhead Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -64.78, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -18.32, reflecting losses generated across the asset base. The company generates approximately 760,672.50 in revenue per employee across its workforce of 711.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Arrowhead Pharmaceuticals, Inc. recorded 16.19M in income tax expense. The company reported a pretax loss of -203.64M and -258.47M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 16, 2026, Arrowhead Pharmaceuticals, Inc.'s stock has gained approximately 141.26% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Arrowhead Pharmaceuticals, Inc. generated 540.84M in revenue and converted that into -258.47M in net income, yielding earnings per share of -1.56. EBITDA reached -162.08M, while operating income came in at -182.92M.

As of June 30, 2026, Arrowhead Pharmaceuticals, Inc. holds 1.29B in cash and equivalents against 794.66M in total debt, resulting in a net debt position of 682.12M. Total book value stands at 376.07M, with working capital of 1.12B providing operational flexibility.

Arrowhead Pharmaceuticals, Inc. produced -47.71M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -12.97M in capital expenditures, free cash flow totaled -60.68M - equivalent to -0.43 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -33.82 and net profit margin of -47.79 provide insight into operational efficiency.

Arrowhead Pharmaceuticals, Inc.'s most recent stock split took place on November 17, 2011 with a 10:1 split ratio.